In this episode, Luka Kulic, MD, Vice President and Global Head of Early Clinical Development in Neuroscience and Rare Diseases at Roche, Basel, Switzerland, discusses the investigational Brainshuttle technology, including results from the BrainShuttle AD clinical trials as a treatment for early Alzheimer disease along with the broader implications of enhanced blood-brain barrier drug delivery in neurology.
Podden och tillhörande omslagsbild på den här sidan tillhör
Practical Neurology. Innehållet i podden är skapat av Practical Neurology och inte av,
eller tillsammans med, Poddtoppen.
